Paolo G Casali

@casali_pg

Medical oncologist, treating sarcoma patients and teaching oncology, advocating rare cancers, hoping for new methods of clinical decision-making and research

Milan, Italy, EU Joined January 2012

787 Following 1.6K Followers 276 Posts

Latest posts 5

Paolo G Casali @casali_pg Sep 26, 2024

EU Joint Action on Networks of Expertise (JANE 1) just closed, knocking on the EU Parliament’s doors asking to politically address the many challenges of cancer healthcare networking. JANE 2 ready to start and give birth to seven new Networks of Expertise on cancer in the EU…

Paolo G Casali @casali_pg Sep 15, 2024

Implementing precision medicine implies a paradigm change in research methodology; implementing personalized medicine implies a paradigm change in methodology of clinical decision-making. Explainable AI is part of the solutions, but these should be made explicit.

Christian Rolfo @ChristianRolfo Sep 14, 2024

Important considerations on global implementation of #precisionmedicine by @VivekSubbiah
#ESMO2024 @myESMO
@isliquidbiopsy

View quoted post on X

Paolo G Casali @casali_pg Jul 30, 2024

All saddened by losing his strong interpretation of a medical specialty in transformation, his total commitment to a disease, his humor in multidisciplinarity…

george demetri @DrSarcoma Jul 29, 2024

A giant among us has departed. Prof. Chris D.M.Fletcher passed away peacefully yesterday in Boston. He impacted our entire field, and he will be missed greatly. It was an honor to work with him and to learn from him.
View quoted post on X

Paolo G Casali @casali_pg Aug 31, 2023

Thanks the new Spanish EU Presidency for hosting the EU Joint Action on Networks of Expertise. Cancer care networking can be such an added value of Europe that its many challenges must be addressed assertively, first working on the interplay between the EU and the national level!

Paolo G Casali @casali_pg Jun 24, 2023

My take: our common advocacy about healthcare networking in the EU should focus on viewing it as networking of national/regional networking and allowing the role of full partners to scientific/professional societies as well as patient advocacy groups.